HK1134445A1 - Intrathecal administration of hgf after spinal cord injury - Google Patents
Intrathecal administration of hgf after spinal cord injuryInfo
- Publication number
- HK1134445A1 HK1134445A1 HK10101945.2A HK10101945A HK1134445A1 HK 1134445 A1 HK1134445 A1 HK 1134445A1 HK 10101945 A HK10101945 A HK 10101945A HK 1134445 A1 HK1134445 A1 HK 1134445A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- hgf
- spinal cord
- cord injury
- intrathecal administration
- intrathecal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2007/053804 WO2008105088A1 (ja) | 2007-02-28 | 2007-02-28 | 脊髄損傷治療薬剤 |
PCT/JP2008/053557 WO2008105507A1 (ja) | 2007-02-28 | 2008-02-28 | 脊髄損傷治療薬剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1134445A1 true HK1134445A1 (en) | 2010-04-30 |
Family
ID=39720932
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK10101945.2A HK1134445A1 (en) | 2007-02-28 | 2010-02-24 | Intrathecal administration of hgf after spinal cord injury |
Country Status (10)
Country | Link |
---|---|
US (1) | US8518880B2 (de) |
EP (1) | EP2116255B1 (de) |
KR (2) | KR20150138413A (de) |
CN (2) | CN101610783B (de) |
CA (1) | CA2675953C (de) |
DK (1) | DK2116255T3 (de) |
ES (1) | ES2412388T3 (de) |
HK (1) | HK1134445A1 (de) |
PT (1) | PT2116255E (de) |
WO (2) | WO2008105088A1 (de) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2351574B1 (de) * | 2008-10-10 | 2016-08-24 | Kringle Pharma, Inc. | Promoter zur regeneration von sehnen-knochen-verbindungsgewebe oder bänder-knochen-verbindungsgewebe |
US9040062B2 (en) | 2010-08-06 | 2015-05-26 | Sumitomo Dainippon Pharma Co., Ltd. | Preparation for treatment of spinal cord injury |
KR101446711B1 (ko) * | 2011-05-23 | 2014-10-06 | 아주대학교산학협력단 | 간세포 성장인자 유전자 및 염기성 나선-고리-나선 계열의 신경형성 전사인자 유전자가 도입된 성체 줄기세포주 및 그의 용도 |
JP6281992B2 (ja) | 2014-09-10 | 2018-02-21 | クリングルファーマ株式会社 | 神経疾患の治療に適したhgf製剤 |
US10478280B2 (en) * | 2017-02-17 | 2019-11-19 | Ethicon Llc | Methods and devices for delivering and securing adjunct materials to a treatment site |
US10716564B2 (en) | 2017-02-17 | 2020-07-21 | Ethicon Llc | Stapling adjunct attachment |
CN109535243B (zh) * | 2019-01-07 | 2019-09-24 | 北京诺思兰德生物技术股份有限公司 | 人肝细胞生长因子突变体及其应用 |
CN113433324B (zh) * | 2021-05-28 | 2022-11-18 | 南通大学 | Nck1蛋白作为标志物在诊断脊髓损伤中的应用 |
EP4488362A1 (de) | 2022-03-01 | 2025-01-08 | Kataoka Corporation | Wachstumsfaktorproduzierende zellen und verfahren zur herstellung davon |
JPWO2023171808A1 (de) * | 2022-03-11 | 2023-09-14 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0678425B2 (ja) | 1984-07-06 | 1994-10-05 | 和光純薬工業株式会社 | 重合体の新規製造法 |
JPH05111382A (ja) | 1991-10-22 | 1993-05-07 | Saito Signal Kenkyusho:Kk | ヒト好酸球細胞株 |
US6143714A (en) * | 1994-10-24 | 2000-11-07 | Regeneron Pharmaceuticals, Inc. | Methods of using hepatocyte growth factor to promote survival, growth and differentiation of motor neurons |
US7033608B1 (en) * | 1995-05-22 | 2006-04-25 | The United States Of America As Represented By The Secretary Of The Army | “Burst-free” sustained release poly-(lactide/glycolide) microspheres |
AU2002349583B2 (en) * | 2001-11-28 | 2007-11-22 | Anges Mg, Inc. | Genetic remedies for neurodegenerative diseases |
WO2004021992A2 (en) * | 2002-09-06 | 2004-03-18 | The General Hospital Corporation | Delivery of therapeutics to the brain and spinal cord |
CN1250287C (zh) * | 2002-11-20 | 2006-04-12 | 中国人民解放军军事医学科学院放射医学研究所 | 一种重组腺病毒在脑缺血、创伤修复和组织粘连治疗中的应用 |
JP2005035945A (ja) * | 2003-07-16 | 2005-02-10 | Cardio Corp | 組織再生複合療法 |
US20090041665A1 (en) | 2004-04-14 | 2009-02-12 | Agency For Science, Technology And Research | Method for gene delivery to neuronal cells |
JPWO2006077675A1 (ja) * | 2005-01-24 | 2008-06-19 | クリングルファーマ株式会社 | 移植臓器の線維化抑制剤 |
JP2007077125A (ja) | 2005-09-16 | 2007-03-29 | Keio Gijuku | 脊髄損傷治療剤 |
JP2007238487A (ja) | 2006-03-07 | 2007-09-20 | Osaka Univ | 脊髄損傷に対する嗅粘膜移植にhgfを用いた神経機能再建法 |
-
2007
- 2007-02-28 WO PCT/JP2007/053804 patent/WO2008105088A1/ja active Application Filing
-
2008
- 2008-02-28 KR KR1020157033326A patent/KR20150138413A/ko not_active Ceased
- 2008-02-28 EP EP08721006.8A patent/EP2116255B1/de active Active
- 2008-02-28 WO PCT/JP2008/053557 patent/WO2008105507A1/ja active Application Filing
- 2008-02-28 CN CN200880004651.0A patent/CN101610783B/zh active Active
- 2008-02-28 KR KR1020097019957A patent/KR101670677B1/ko active Active
- 2008-02-28 DK DK08721006.8T patent/DK2116255T3/da active
- 2008-02-28 CA CA2675953A patent/CA2675953C/en active Active
- 2008-02-28 PT PT87210068T patent/PT2116255E/pt unknown
- 2008-02-28 ES ES08721006T patent/ES2412388T3/es active Active
- 2008-02-28 CN CN201510716455.8A patent/CN105311620A/zh active Pending
-
2009
- 2009-08-27 US US12/548,881 patent/US8518880B2/en active Active
-
2010
- 2010-02-24 HK HK10101945.2A patent/HK1134445A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
EP2116255B1 (de) | 2013-04-10 |
WO2008105088A1 (ja) | 2008-09-04 |
EP2116255A1 (de) | 2009-11-11 |
CA2675953C (en) | 2016-05-10 |
PT2116255E (pt) | 2013-06-21 |
CN105311620A (zh) | 2016-02-10 |
ES2412388T3 (es) | 2013-07-11 |
US20100081617A1 (en) | 2010-04-01 |
EP2116255A4 (de) | 2011-05-04 |
CA2675953A1 (en) | 2008-09-04 |
US8518880B2 (en) | 2013-08-27 |
WO2008105507A1 (ja) | 2008-09-04 |
DK2116255T3 (da) | 2013-05-13 |
KR20150138413A (ko) | 2015-12-09 |
US20120021040A9 (en) | 2012-01-26 |
KR101670677B1 (ko) | 2016-11-01 |
CN101610783A (zh) | 2009-12-23 |
KR20090118078A (ko) | 2009-11-17 |
CN101610783B (zh) | 2016-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1134445A1 (en) | Intrathecal administration of hgf after spinal cord injury | |
HK1219272A1 (zh) | 螺羥吲哚化合物及其作為治療劑的用途 | |
HK1211889A1 (en) | Therapeutic use of diaminophenothiazines | |
EP2621588A4 (de) | Verfahren und zusammensetzungen zur krankheitsbehandlung durch inhalation | |
GB0803018D0 (en) | Therapeutic compounds and their use | |
GB0804685D0 (en) | Therapeutic compounds and their use | |
HK1200372A1 (en) | Methods of vaccine administration | |
IL236360A0 (en) | Inhalable medicine | |
GB0807609D0 (en) | Therapeutic compounds and their use | |
EP2268281A4 (de) | Thienopyrrole und pyrrolothiazole als neue therapiemittel | |
GB0817208D0 (en) | Therapeutic apsap compounds and their use | |
IL215835A (en) | Carboxamide compounds and their use as a drug | |
GB0905196D0 (en) | Patient therapy equipment | |
ZA201301385B (en) | Therapeutic uses of 1-[2,4-dimethyl-phenylsulfanyl)phenyl]piperazine | |
GB0812913D0 (en) | Therapeutic compounds and their use | |
HRP20180744T1 (hr) | Terapeutska cjepiva | |
HK1182712A1 (en) | Therapeutic agents 976 976 | |
GB0721616D0 (en) | Treatment of spinal cord injury | |
HK1152247A1 (en) | Methods of treatment employing prolonged continuous infusion of belinostat belinostat | |
GB0802128D0 (en) | Therapeutic compounds and their use | |
GB0815134D0 (en) | Therapeutic compounds and their use | |
GB0820260D0 (en) | Treatment of spinal cord injury | |
GB0821539D0 (en) | Therapeutic compounds and their use | |
GB0801424D0 (en) | Therapeutic vaccines | |
GB0802405D0 (en) | Therapeutic vaccines |